small molecule

LUMIGAN

BIMATOPROST

Loss of exclusivity—loss of exclusivity

CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	LUMIGAN
Active ingredient	BIMATOPROST
Strength	0.03% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	SOLUTION/DROPS
Route	OPHTHALMIC
Modality	Small molecule
FDA approval	March 2001
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.